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ABSTRACT 24 
Canine influenza viruses (CIVs) are the causative agents of canine influenza, a 25 
contagious respiratory disease in dogs, and include the equine-origin H3N8 and the 26 
avian-origin H3N2. Influenza A virus (IAV) non-structural protein 1 (NS1) is a virulence 27 
factor essential for counteracting the innate immune response. Here, we evaluated the 28 
ability of H3N8 CIV NS1 to inhibit host innate immune responses. We found that H3N8 29 
CIV NS1 was able to efficiently counteract interferon (IFN) responses but was unable to 30 
block general gene expression in human or canine cells. Such ability was restored by a 31 
single amino acid substitution in position 186 (K186E) that resulted in NS1 binding to 32 
the 30-kDa subunit of the cleavage and polyadenylation specificity factor (CPSF30), a 33 
cellular protein involved in pre-mRNA processing. We also examined the frequency 34 
distribution of K186 and E186 among H3N8 CIVs and equine influenza viruses (EIVs), 35 
the ancestors of H3N8 CIV, and experimentally determined the impact of amino acid 36 
186 in the ability of different CIV and EIV NS1s to inhibit general gene expression. In all 37 
cases, the presence of E186 was responsible for the control of host gene expression. 38 
Contrastingly, the NS1 protein of H3N2 CIV harbors E186 and blocks general gene 39 
expression in canine cells. Altogether, our results confirm previous studies on the strain-40 
dependent ability of NS1 to block general gene expression. Moreover, the observed 41 
polymorphism on amino acid 186 between H3N8 and H3N2 CIVs might be the result of 42 
adaptive changes acquired during long-term circulation of avian-origin IAVs in 43 
mammals.  44 
 45 
 46 
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IMPORTANCE 47 
Canine influenza is a respiratory disease of dogs caused by two CIV subtypes, the 48 
H3N8 and H3N2 viruses of equine and avian origin, respectively. Influenza NS1 is the 49 
main viral factor responsible for the control of host innate immune responses and 50 
changes in NS1 can play an important role in host adaptation. Here we assessed the 51 
ability of H3N8 CIV NS1 to inhibit host innate immune responses and gene expression. 52 
The H3N8 CIV NS1 did not block host gene expression but this activity was restored by 53 
a single amino acid substitution (K186E), which was responsible for NS1 binding to the 54 
host factor CPSF30. In contrast, the H3N2 CIV NS1, that contains E186, blocks general 55 
gene expression. Our results suggest that the ability to block host gene expression is 56 
not required for influenza replication in mammals but might be important in the long-57 
term adaptation of avian-origin influenza viruses to mammals. 58 
 59 
 60 
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INTRODUCTION 69 
Influenza A viruses (IAVs) are single-stranded, negative-sense, segmented RNA 70 
viruses that belong to the Orthomyxoviridae family (1, 2). They are classified on the 71 
basis of the two major surface glycoproteins, hemagglutinin (HA) and neuraminidase 72 
(NA) (1, 2). While IAVs mostly circulate in wild aquatic birds (3-6), some have become 73 
established as novel lineages in various avian and mammalian hosts (7, 8). In addition, 74 
many IAVs cause sporadic spillover infections in humans and other mammals (9, 8, 4).  75 
Two canine influenza viruses (CIVs) have emerged in the last decade. The first one 76 
is of the H3N8 subtype, and was first reported during an outbreak of respiratory disease 77 
in Florida, USA, in 2004 (10-12). H3N8 CIV originated from equine influenza virus (EIV), 78 
an avian-origin IAV that has been circulating in horses since the 1960s (10, 13). Another 79 
recently emerged CIV is the avian-origin H3N2 subtype, originated in China, which has 80 
been circulating in Asia since ~2006 (14) and was introduced to North America in 2015 81 
(15). Since CIVs are the result of successful cross-species virus transfers, it is of 82 
interest to understand how they have succeeded in their new host, and whether they 83 
constitute potential threats to the global canine population (16, 7, 8) and perhaps to 84 
other species, including humans. Understanding the determinants of pathogenesis and 85 
host range of CIVs is essential to shed light on the mechanisms of disease in dogs and 86 
to provide insights into the general mechanisms of IAV host range in other species.  87 
The host innate immune responses constitute an essential part of the host defenses 88 
that restrict viral infections. These are mainly mediated by the induction of an interferon 89 
(IFN) response that results in the expression of a broad range of IFN-stimulated genes 90 
(ISGs), some of which possess antiviral activity (17). IAVs encode the non-structural 91 
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protein 1 (NS1), a multifunctional protein that is a molecular determinant of IAV 92 
virulence and is the main viral antagonist of the IFN response (18-20). NS1 acts at 93 
multiple levels of the IFN signaling pathway: it has been shown to impair the expression 94 
of ISGs (18) and to directly inhibit specific ISGs, such as protein kinase R (PKR) (18) 95 
and 2’-5’ oligoadenylate synthetase and ribonuclease L (RNase L) (21). NS1 can also 96 
inhibit the production of IFN at the pre-transcriptional level by sequestering double-97 
stranded (ds)RNA and subsequently decreasing the activation of retinoic acid inducible 98 
gene 1 (RIG-I) (22-24), or by inhibiting the tripartite motif family (TRIM)-25-mediated 99 
RIG-I ubiquitination (22, 24). NS1 can also impair the IFN response by blocking general 100 
host gene expression by binding the 30-kDa subunit of the cleavage and 101 
polyadenylation specificity factor 30 (CPSF30). The ability of NS1 to bind CPSF30 and 102 
block host gene expression is not conserved in all IAVs. Indeed, it has been shown that 103 
naturally occurring IAVs that infect humans, such as the swine-origin 2009 pandemic 104 
H1N1 (pH1N1) virus (25), the avian-origin H7N9 (26) and H5N1 (27) viruses, as well as 105 
the laboratory strain A/Puerto Rico/8/34 (PR8) (28), do not bind CPSF30. The amino 106 
acid(s) involved in the interaction with CPSF30 have been mapped to different NS1 107 
residues (26, 29, 30, 25, 28, 31-34). 108 
Here we examined the ability of H3N8 CIV NS1 to counteract the IFN response, and 109 
found that this protein blocks the induction of IFN and ISGs without blocking general 110 
host gene expression. However, a single amino acid substitution (K186E) results in the 111 
recovery of the ability to block general host transcription. These results confirm the 112 
notion that the specific functions of NS1 protein are strain-dependent and likely vary 113 
with the level of virus adaptation to the host. 114 
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MATERIALS AND METHODS  115 
Cell lines  116 
Human embryonic kidney 293T, HEK293T (American Type Culture Collection, 117 
ATCC CRL-11268); Madin-Darby canine kidney, MDCK (ATCC CCL-34); and BSR-T7 118 
(kindly provided by Dr. Karl-Klaus Conzelmann) (35) cells were grown at 37°C with 5% 119 
CO2 in Dulbecco’s modified Eagle’s medium (DMEM; Mediatech, Inc.), 10% fetal bovine 120 
serum (FBS), and 1% PSG (penicillin, 100 units/ml; streptomycin 100 μg/ml; L-121 
glutamine, 2 mM) (36, 37). A72 cells (ATCC CRL-1542) were grown in 50/50 McCoy’s 122 
5A (Gibco)/Leibovitz’s L-15 (Gibco) with 5% FBS and 1% PSG.   123 
Virus rescue 124 
Virus rescues were performed as previously described (38, 37). Briefly, co-cultures 125 
(1:1) of HEK293T/MDCK cells (6-well plate format, 106 cells/well, triplicates) were co-126 
transfected in suspension, using Lipofectamine 2000 (LPF2000; Invitrogen), with 1 µg 127 
each of the seven A/canine/NY/dog23/2009 H3N8 ambisense wild-type (WT) plasmids 128 
(pDZ-PB2, -PB1, -PA, -NP, -NA, -M, -HA) (13) plus the ambisense WT (pDZ-NS) or 129 
mutant K186E (pDZ-NS K186E) plasmids. At 12 hours post-transfection (hpt), the 130 
medium was replaced with DMEM containing 0.3% bovine serum albumin (BSA), 1% 131 
PSG, and 1 µg/ml tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin 132 
(Sigma). At 48 hpt, tissue culture supernatants (TCS) were used to infect fresh 133 
monolayers of MDCK cells (6-well plate format, 106 cells/well, triplicates). At 3 days 134 
post-infection (pi), recombinant viruses were plaque purified and scaled up in MDCK 135 
cells. Stocks were titrated by plaque assay on MDCK cells (38, 37), and the identity of 136 
the NS segment was confirmed by restriction analysis and sequencing.  137 
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Virus growth kinetics and immunostaining 138 
To evaluate viral growth kinetics, MDCK cells or A72 cell (12-well plate format, 5x105 139 
cells/well, triplicates) were infected at low (0.001) and high (3) multiplicity of infection 140 
(MOI) and the TCS were collected at the indicated time points. Viral titers were 141 
determined by immunofocus assay (fluorescent forming units [FFU]) in MDCK cells as 142 
previously described (38, 37). The mean value and standard deviation were calculated 143 
using Microsoft Excel software. For the immunostaining, confluent MDCK cell 144 
monolayers (6-well plate format, 106 cells/well) were infected with 10-fold serial dilutions 145 
of H3N8 CIV WT or K186E viruses. After infection, monolayers were overlaid with agar 146 
and incubated for 72 h at 33ºC. Then, cells were fixed with 4% paraformaldehyde 147 
(PFA), and the overlays were removed. Fixed cells were then permeabilized (0.5% 148 
Triton X-100 in PBS for 15 min at room temperature) and used for immunostaining as 149 
previously described (38, 37) using anti-NP MAb (ATCC, HB-65) (American Type 150 
Culture Collection, ATCC) and vector kits (Vectastain ABC kit and DAB HRP Substrate 151 
Kit: Vector), according to manufacturer’s specifications.  152 
RT-PCRs 153 
Total RNA from CIV or EIV-infected (MOI 3) MDCK cells (6-well plate format, 106 154 
cells/well) was collected at 18 hpi. and purified using TRIzol (Invitrogen) according to 155 
the manufacturer’s specifications. cDNA synthesis for NS viral (v)RNAs or NS1 mRNAs 156 
were performed using SuperScript® II Reverse Transcriptase (Invitrogen) and specific 157 
primers. cDNAs were used as templates for semi-quantitative PCR with primers specific 158 
for the NS vRNA (A/canine/NY/dog23/2009 H3N8) or NS1 mRNAs 159 
(A/canine/Florida/2004 H3N8, A/equine/Pennsylvania/1/2007 H3N8, 160 
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A/equine/Miami/1963 H3N8 and A/canine/IL/41915/2015 H3N2). Primer sequences are 161 
available upon request. Influenza A/equine/Pennsylvania/1/2007 and 162 
A/equine/Miami/1963 H3N8 were obtained from BEI Resources (NR-13426 and NR-163 
3175, respectively). Influenza A/canine/Florida/2004 H3N8 and influenza 164 
A/canine/IL/41915/2015 H3N2 were provided by the Baker Institute for Animal Health at 165 
Cornell University.  166 
For quantitative RT-PCRs (qRT-PCRs), MDCK cells (12-well plate format, 5x105 167 
cells/well, triplicates) were mock infected or infected (MOI of 3) with NS1 WT and 168 
K186E H3N8 CIVs. At 12 or 24 hpi, total RNA was extracted using an RNeasy minikit 169 
(Qiagen) following the manufacturer's recommendations. Reverse transcription 170 
reactions were performed at 37°C for 2 h using the high-capacity cDNA transcription kit 171 
and an oligodT primer to amplify mRNAs. Quantitative PCRs were performed using 172 
TaqMan IFNβ and IFN-induced protein with tetratricopeptide repeats 2 (IFIT2) assays 173 
(Applied Biosystems) specific for the Canis familiaris (dog) genes (Cf03644503_s1 and 174 
Cf02645026_m1, respectively). Quantification was achieved using the 2−ΔΔCT method 175 
(39). 176 
Plasmids 177 
To engineer polymerase II expression pCAGGS plasmids (40) containing the NS1 178 
sequences fused to an HA epitope tag (YPYDVPDYA) at the N terminus (pCAGGS-HA-179 
NH2) (23) we used standard molecular biology techniques. The different NS1 genes 180 
were amplified by RT-PCR using oligonucleotides with the appropriate flanking 181 
restriction sites (SmaI and XhoI) for cloning into pCAGGS-HA-NH2. NS1 open reading 182 
frames were also cloned in a pGEM-T plasmid (Promega) to introduce the different 183 
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mutations by site-directed mutagenesis using specific primers. To abolish NS mRNA 184 
splicing, two silent mutations were introduced at nucleotides (nt) 501 and 504 of NS1 185 
(30, 33). NS1 mutants were subcloned from the pGEM-T to the pCAGGS-HA-NH2 186 
using SmaI and XhoI. Plasmids encoding NS1 variants under the control of the phage 187 
T7 polymerase were obtained by subcloning NS1 from the pCAGGS-HA-NH2 plasmids 188 
into pcDNA3 plasmid using EcoRI and XbaI restriction enzymes. pCAGGS and pDNA3 189 
plasmids encoding the NS1 proteins of influenza A/Puerto Rico/8/34 (PR8) and 190 
influenza A/Brevig Mission/01/1918 (BM/18) H1N1 viruses were previously described 191 
(28, 23). To generate a H3N8 CIV containing the mutation K186E, the mutated NS viral 192 
segment was cloned into the ambisense pDZ plasmid for virus rescue. All the plasmid 193 
constructs were confirmed by sequencing (ACGT, Inc.). Primers used for the 194 
construction of the different plasmids are available under request. 195 
Inhibition of host gene expression 196 
To evaluate the effect of viral NS1 proteins on host protein synthesis, HEK293T or 197 
MDCK cells (12-well plate format, 3x105 cells/well, triplicates) were transiently co-198 
transfected, using LPF2000, with 2 µg/well of pCAGGS-HA NH2 NS1 protein 199 
expression plasmids, or an empty plasmid as a control, together with 50 ng/well of 200 
pCAGGS plasmids expressing the green fluorescent protein, GFP (28) and Gaussia 201 
luciferase, Gluc (41). For T7-driven expression, BSR-T7 cells (12-well plate format, 202 
3x105 cells/well, triplicates) were transiently co-transfected, as indicated above, with 2 203 
µg/well of pCAGGS-HA NH2 NS1 protein expression plasmids, or an empty plasmid as 204 
a control, together with 0.5 µg/well of the reporter expression plasmids pCITE-FFLuc 205 
and pCITE-GFP, which express Firefly luciferase (FFluc) or GFP under the control of 206 
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the T7 promoter (38). At 24 hpt , cells were analyzed for GFP expression under a 207 
fluorescent microscope and Gluc (HEK293T and MDCK cells) or FFluc (BSR-T7 cells) 208 
activities were quantified from TCS (Gluc) or cell lysates (FFluc) using a Biolux Gaussia 209 
luciferase reagent (New England Bio-Labs) or a FFluc luciferase reporter buffer 210 
(Promega) and a Lumicount luminometer. The mean values and standard deviations 211 
were calculated using Microsoft Excel software. 212 
Inhibition of IFN-β and ISRE promoters  213 
The assays to evaluate the effect of NS1 proteins on the inhibition of IFN-β and IFN 214 
stimulated response element (ISRE) promoters have been previously described (28). 215 
Briefly, HEK293T cells (12-well plate format, 3x105 cells/well, triplicates) were co-216 
transfected with 1 µg/well of the pCAGGS-HA NH2 NS1-expressing plasmids, or empty 217 
plasmid as control, together with 0.5 µg/well of plasmids expressing FFluc under the 218 
control of the IFN-β or the ISRE promoters (pIFN-β -FFluc and pISRE-FFluc, 219 
respectively) (28), and 0.5 µg/well of plasmids expressing GFP or RFP fused to the 220 
chloramphenicol acetyltransferase (CAT) driven by the IFN-β or the ISRE promoter 221 
(pIFNβ-GFP/CAT and pISRE-RFP/CAT, respectively) using a calcium phosphate-based 222 
mammalian transfection kit (Stratagene). At 18 hpt, cells were infected (MOI 3) with 223 
Sendai virus (SeV), Cantell strain (28), and at 18 hpi cells were analyzed for IFN-β or 224 
ISRE promoter activation by GFP (IFN-β) or RFP (ISRE) expression under a fluorescent 225 
microscope. FFluc activity was quantified from cell lysates using a FFluc luciferase 226 
reporter buffer (Promega) and a Lumicount luminometer (PacKard). Reporter gene 227 
activation is shown as relative light units (RLU) compared to SeV-infected cells in the 228 
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absence of NS1 protein (empty plasmid). The mean values and standard deviations 229 
were calculated using Microsoft Excel software. 230 
Protein gel electrophoresis and Western blot analysis 231 
Total proteins from cells lysates were separated using 10% SDS-polyacrylamide 232 
gels and transferred to nitrocellulose membranes. Membranes were blocked for 1 h with 233 
5% dried skim milk in phosphate-buffered saline (PBS) containing 0.1% Tween 20 (T-234 
PBS) and incubated overnight at 4°C with anti-HA (for NS1; Sigma) or anti-FLAG (for 235 
F2/F3 CPSF30; Sigma) polyclonal antibodies (pAb). A monoclonal antibody (mAb) 236 
specific for actin (Sigma) was used as an internal loading control. Bound primary 237 
antibodies were detected with horseradish peroxidase (HRP)-conjugated antibodies 238 
(GE Healthcare) against immunoglobulins of different species (mouse or rabbit). 239 
Proteins were detected by chemiluminescence using the SuperSignal West Femto 240 
maximum-sensitivity substrate (Thermo Scientific) following the manufacturer's 241 
recommendations and photographed using a Kodak Image Station.  242 
NS1 interaction with CPSF30  243 
HA-tagged NS1 proteins were synthesized in vitro using pcDNA3 plasmids and the 244 
TNT7 transcription/translation kit (Promega) following the manufacturer's 245 
recommendations. HEK293T cells (6-well format, 1.5 ×106 cells/well) were transiently 246 
transfected with 2 µg/well of a pCAGGS plasmid expressing a FLAG-tagged version of 247 
the F2/F3 region of the human CPSF30 (FLAG-F2/F3 CPSF30) (34). At 48 hpt, cells 248 
were lysed in 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 0.5 mM EDTA, 5% glycerol, and 249 
1% Triton X-100 supplemented with a complete mini protease inhibitor cocktail (Pierce). 250 
Cleared cell lysates were incubated overnight at 4°C with the in vitro-synthesized NS1 251 
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proteins and 20 μl of an anti-FLAG affinity resin (Sigma). After extensive washing, 252 
precipitated proteins were dissociated from the resin using Laemmli buffer and analyzed 253 
by Western blotting as described above. 254 
 255 
 256 
 257 
 258 
 259 
 260 
 261 
 262 
 263 
 264 
 265 
 266 
 267 
 268 
 269 
 270 
 271 
 272 
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RESULTS 273 
H3N8 CIV NY09 NS1 protein does not block host gene expression in human or 274 
canine cells  275 
To evaluate whether H3N8 CIV NS1 protein could block host gene expression, human 276 
HEK293T or canine MDCK cells were co-transfected with plasmids encoding GFP or GLuc 277 
together with individual plasmids encoding the NS1 genes of either A/canine/NY/dog23/2009 278 
H3N8 (CIV NY09), A/Puerto Rico/8/34 H1N1 (PR8) and A/Brevig Mission/1/18 H1N1 (BM/18) 279 
(Fig. 1). Cells transfected with empty plasmid were also used as an internal control. We have 280 
previously described that PR8 NS1 is not able to block host gene expression. However such 281 
ability can be restored by introducing amino acid substitutions S103F and I106M in PR8 NS1 282 
(28). Contrary, the NS1 protein from BM/18 is a strong inhibitor of host gene expression (42, 283 
28). At 24 hpt, GFP expression was evaluated using fluorescence microscopy (Figs. 1A and 284 
1D) and Gluc expression levels were quantified in a luminometer (Figs. 1B and 1E). As 285 
expected, PR8 NS1 protein did not block expression of GFP and/or Gluc whereas BM/18 NS1 286 
inhibited protein expression of both reporter genes (28). CIV NY09 NS1 protein did not inhibit 287 
either GFP or Gluc expression. The NS1 proteins from PR8 or CIV NY09 were detected by 288 
Western blot (Figs. 1C and 1F) but this was not the case for the NS1 protein of BM/18, 289 
because this NS1 is inhibiting its own synthesis (28). Our results obtained with both human 290 
(Figs. 1A-1C) and canine (Figs. 1D-1F) cells were similar, suggesting that the inability of CIV 291 
NY09 NS1 protein to block host gene expression does not depend on the origin of the cells. 292 
A single substitution (K186E) in the NS1 protein of H3N8 CIV NY09 restores its 293 
ability to block host gene expression  294 
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To identify the amino acid(s) in H3N8 CIV NY09 NS1 protein responsible for the lack 295 
of inhibition of host gene expression we aligned the NS1 protein sequences of the 296 
viruses used in our reporter-based assay (Fig. 1) and also included two additional 297 
viruses: A/Texas/36/91 H1N1 (TX/91, which binds CPSF30), and the pandemic 298 
A/California/04/09 H1N1 (pH1N1, which does not bind CPSF30) (Fig. 2A). We identified 299 
eight amino acids (P77, D96, T112, E139, F185, K186, K193 and I194) in the H3N8 CIV 300 
NY09 NS1 protein that could have a potential role in the lack of inhibition of host gene 301 
expression (Fig. 2A, gray). To test the contribution of these residues to the inhibition of 302 
host gene expression, we introduced mutations P77L, D96E, T112A, E139D, F185L, 303 
K186E, K193R and I194V into the CIV NY09 NS1 protein and tested their ability to 304 
block general gene expression in our reporter-based assay in MDCK cells (Figs. 2B-305 
2C). A single substitution (K186E) introduced the ability of H3N8 CIV NY09 NS1 protein 306 
to inhibit general host gene expression as measured by GFP (Fig. 2B) and Gluc (Fig. 307 
2C) expression levels. Moreover, the K186E mutant construct was the only one that 308 
could not be detected by Western blot, suggesting it was inhibiting its own expression 309 
(Fig. 2D).  310 
We next evaluated if the ability of H3N8 CIV NY09 NS1 K186E protein to inhibit host 311 
gene expression was dose-dependent (Figs. 3A-3B). MDCK cells were co-transfected 312 
with the pCAGGS plasmid expressing Gluc together with different amounts of the 313 
plasmids encoding CIV NY09 NS1 WT or the K186E mutant. Clearly, CIV NY09 NS1 314 
K186E protein showed a dose-dependent inhibitory effect on Gluc expression (Fig. 3A) 315 
and inhibition of its own expression (Fig. 3B). H3N8 CIV NY09 NS1 WT protein did not 316 
have an effect on reporter gene expression (Fig. 3A) and was detected by Western blot 317 
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only when 2, 1 or 0.5 µg of plasmid was transfected, most likely because of the limit of 318 
detection of the assay (Fig. 3B).  319 
To test if CIV NY09 NS1 K186E protein inhibition of host gene expression was due 320 
to inhibiting transcripts produced by the cellular RNA polymerase II, we used a variation 321 
of the assay where reporter gene expression (GFP and FFluc) was under the control of 322 
a bacteriophage T7 polymerase promoter (38). BSR-T7 cells constitutively expressing 323 
T7 RNA polymerase (35) were co-transfected with reporter GFP and FFluc plasmids 324 
under the control of the T7 polymerase, together with plasmids encoding the H3N8 CIV 325 
NY09 NS1 WT or K186E, the NS1 proteins from PR8 or BM/18 or empty plasmid as 326 
internal controls. At 24 hpt, GFP and FFluc expressions were analyzed using 327 
fluorescence microscopy (Fig. 3C) or a luminometer (Fig. 3D), respectively. In this 328 
assay, none of the NS1 constructs showed any effect on reporter gene expression, 329 
demonstrating that only nuclear transcripts produced by cellular RNA polymerase II 330 
were targets of the inhibitory effect of NS1 WT or mutant constructs. As expected, when 331 
NS1 protein expression was analyzed by Western blot, H3N8 CIV NY09 K186E and 332 
BM/18 NS1 proteins were not detected (Fig. 3E).  333 
K186E substitution introduces the ability of H3N8 CIV NY09 NS1 protein to 334 
bind to CPSF30  335 
It has been shown that NS1 proteins of some IAV strains interact with CPSF30, 336 
blocking host gene expression (26, 29, 30, 25, 28, 31-34). The interaction of NS1 and 337 
CPSF30 is mediated by the effector domain of the former and the F2/F3 region of the 338 
latter (26, 29, 30, 25, 28, 31-34). Importantly, the F2/F3 region of CPSF30 is conserved 339 
between species including the ones relevant for this study (human, dogs and horses) 340 
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(data not shown). Given the ability of the H3N8 CIV NY09 NS1 K186E protein to inhibit 341 
host gene expression, we hypothesized that this phenotype was due to a restored ability 342 
to bind CPSF30. We evaluated the interaction between H3N8 CIV NY09 NS1 WT or 343 
K186E proteins and CPSF30 by co-immunoprecipitation (Fig. 4A). Cell extracts from 344 
human HEK293T cells transfected with a plasmid encoding an N-terminal FLAG-tagged 345 
F2/F3 region of CPSF30 (34) were incubated with in vitro transcribed and translated 346 
H3N8 CIV NY09 NS1 WT and K186E proteins or with PR8 NS1 protein as control, and 347 
agarose beads conjugated with an anti-FLAG antibody. As expected, PR8 NS1 and 348 
H3N8 CIV NY09 NS1 WT proteins did not co-immunoprecipitate with CPSF30 (28), 349 
however, CIV NY09 NS1 K186E protein did (Fig. 4A).  The three dimensional structure 350 
of influenza A/Udorn/72 H3N2 NS1 bound to the F2/F3 domain of CPSF30, shows that 351 
NS1 residue 186 is closely located to the CPSF30 protein (Fig. 4B), providing a likely 352 
explanation for the effect of this amino acid change in the binding to CPSF30 (29). 353 
Altogether, our results indicate that the K186E substitution restores the ability of H3N8 354 
CIV NY09 NS1 protein to bind CPSF30. 355 
Effect of H3N8 CIV NY09 NS1 protein on inhibition of IFN responses 356 
To analyze the effect of H3N8 CIV NY09 NS1 WT and K186E proteins to counteract 357 
IFN responses, human HEK293T cells were co-transfected with pCAGGS plasmids 358 
expressing PR8, BM/18, CIV NY09 WT and K186E NS1 proteins, together with 359 
plasmids expressing FFluc and GFP under the control of the IFN-β promoter (Figs. 360 
5A-5C) or FFluc and RFP under the control of an ISRE promoter (Figs. 5D-5F). At 18 361 
hpt, cells were mock-infected or infected with the Cantell strain of SeV for 18 h to induce 362 
activation of both promoters. Then, IFN-β and ISRE promoter activation was 363 
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determined by measuring expression levels of GFP or RFP (Figs. 5A and 5D) and 364 
FFluc (Figs. 5B and 5E). As expected, SeV infection induced robust activation of the 365 
respective promoters (IFN-β, Figs. 5A-5B; and ISRE, Figs. 5D-5E) in cells transfected 366 
with empty plasmid. On the other hand, and consistent with previous results (18), SeV-367 
infected cells transfected with the different NS1-expressing plasmids showed less 368 
activation of both promoters compared with those transfected with empty plasmid. 369 
Moreover, when NS1 protein expression levels were evaluated by Western blot, only 370 
PR8 and H3N8 CIV NY09 WT NS1 proteins were detected (Figs. 5C and 5F). These 371 
results indicate that K186E substitution did not affect the ability of H3N8 CIV NY09 NS1 372 
protein to inhibit SeV-mediated activation of IFN- or ISRE promoters. In addition, these 373 
results suggest that H3N8 CIV NY09 NS1 protein has IFN antagonistic properties 374 
despite not being able to block general host gene expression in either human or canine 375 
cells (Fig. 1). 376 
Generation and characterization of WT and K186E H3N8 NY09 CIVs 377 
To analyze whether the H3N8 CIV NY09 NS1 K186E mutation had an effect on virus 378 
replication, we generated recombinant H3N8 NY09 CIVs containing the WT or the 379 
K186E substitution in NS1 (13). We first confirmed the identity of the recombinant 380 
viruses by RT-PCR and restriction analysis of the NS segment. K186E substitution 381 
removed a SwaI restriction site in NS1, which was used as a genetic marker to 382 
distinguish H3N8 NY09 WT and K186E recombinant CIVs (Fig. 6A). In addition, the NS 383 
viral (v)RNA was sequenced to ensure the absence of additional mutations (data not 384 
shown). The amino acid substitution K186E in H3N8 NY09 NS1 protein did not affect 385 
the amino acid sequence of the viral NEP, which is produced using an alternative 386 
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splicing mechanism from the same NS vRNA (18, 19). Next, we compared both viruses’ 387 
ability to spread between neighboring cells by plaque assay in MDCK cells (Fig. 6B), as 388 
well as their multicycle and single cycle growth kinetics in MDCK (Figs. 6C and 6D, 389 
respectively) and in A72 (Figs. 6E and 6F, respectively) canine cells. Canine A72 cells 390 
are a well-established tissue culture system to study viruses infecting dogs, including 391 
parvovirus and CIV (13, 43). CIV NY09 NS1 K186E displayed a similar plaque 392 
phenotype in MDCK cells as the parental virus (Fig. 6B). Interestingly, multicycle 393 
replication experiments using MDCK (Fig. 6C) or A72 (Fig. 6E) cells infected at low 394 
MOI (0.001) revealed that the recombinant H3N8 NY09 WT and K186E CIVs grew with 395 
similar kinetics. However, when cells were infected at high MOI (3), the WT virus grew 396 
at lower titers than the K186E mutant in both cell lines (Figs. 6D and 6F). These data 397 
indicate that the defect in efficient CPSF30 binding and inhibition of host protein 398 
expression by CIV NY09 NS1 protein only slightly affects virus replication in vitro, as 399 
previously described for other IAVs (30, 18, 25, 28, 33).  400 
To further analyze the ability of the recombinant NY09 H3N8 NS1 WT and K186E 401 
mutant CIVs to inhibit ISG IFIT2 (Fig. 7A and 7B) or IFNβ (Fig. 7C and 7D) responses, 402 
MDCK cells were infected (MOI 3) and at 12 (Fig. 7A and 7C) or 24 (Fig. 7A and 7C) 403 
hpi, expression of IFIT2 and IFNβ were measured at the mRNA level by qRT-PCR. 404 
Interestingly, the levels of IFIT2 expression were higher in NY09 H3N8 NS1 WT-405 
infected MDCK cells than in mutant K186E-infected cells at both times pi (Fig. 7A and 406 
7B). These data indicate that the amino acid change K186E increase the ability of NS1 407 
to inhibit ISGs during viral infection. On the other hand, both viruses were able to inhibit 408 
the expression of IFNβ at similar levels (Fig. 7C and 7D).  409 
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 410 
The ability of H3N8 CIV NS1 protein to block host gene expression was lost 411 
during virus evolution  412 
We next investigated if the inability to block host gene expression by H3N8 CIV NS1 413 
protein was conserved along its evolution by comparing the NS1 amino acid sequences 414 
of H3N8 viruses phylogenetically related to CIV NY09, including A/canine/Florida/2004 415 
H3N8 (CIV FL04) and the equine influenza viruses (EIVs) 416 
A/equine/Pennsylvania/1/2007 H3N8 (EIV Pen07) and the early A/equine/Miami/1963 417 
H3N8 (EIV Mi63) (Fig. 8). The K186 was mostly conserved as EIV Mi63 is the only virus 418 
that displays E186 (Fig. 8A and Fig. 9). We evaluated the ability of the aforementioned 419 
NS1 proteins to block host gene expression in MDCK cells, as previously described 420 
(Fig. 1). As expected, only the NS1 protein of EIV Mi63 blocked expression of GFP 421 
and/or Gluc (Figs. 8B and C). Similar results were obtained when NS1 protein 422 
expression levels were evaluated by Western blot (Fig. 8D). We confirmed that amino 423 
acid substitution E186K was responsible for the lack of inhibition of host gene 424 
expression when we introduced E186 in CIV FL04 and EIV Pen07 NS1 proteins and 425 
K186 in EIV Mi63 NS1  (Figs. 8B-8D).  426 
EIV Mi63 was the first EIV isolated after the virus was transmitted from an avian host 427 
to horses, suggesting that the ability to inhibit host gene expression was lost during the 428 
evolution of EIV in horses but before the virus was transmitted to dogs in 2004 (Fig. 9). 429 
To assess the timeline describing the period over which amino acid substitution E186K 430 
was incorporated into NS1, the percent of H3N8 EIVs and CIVs strains whose NS1 431 
sequence encoded the different amino acids were plotted (Fig. 9). Notably, database 432 
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analysis suggests that amino acid substitution E186K occurred early in the 70s in EIVs 433 
and has remained stable since then (Fig. 9). Moreover, all H3N8 CIV strains analyzed 434 
encode amino acid K186, indicating that since EIV transferred into dogs in 2004, K186 435 
has been maintained (Fig. 9). 436 
The avian-origin H3N2 CIV NS1 protein is able to block host gene expression  437 
To determine if the inability to block general gene expression was a feature of 438 
influenza viruses of dogs, we next examined the NS1 sequences of H3N2 CIVs as this 439 
lineage has a different origin from H3N8 CIV. Interestingly, all the H3N2 CIV NS1 440 
proteins exhibit E186 (data not shown), suggesting that the NS1 proteins of this lineage 441 
would block host gene expression. To confirm this, we co-transfected MDCK cells with 442 
the reporter expressing plasmids (Fig. 1) and the H3N2 CIV NS1 protein efficiently 443 
inhibited the expression of GFP and Gluc (Figs. 10A and 10B, respectively). Moreover, 444 
Western blot analysis further confirmed the ability of H3N2 CIV NS1 protein to inhibit 445 
host gene expression, including its own expression (Fig. 10C). Notably, this phenotype 446 
was reverted when the amino acid substitution E186K was introduced into the H3N2 447 
CIV NS1 protein (Fig. 10). These data suggests that the ability to block general host 448 
gene expression is strain-dependent, similar to what has been observed with human 449 
influenza viruses.  450 
 451 
 452 
 453 
 454 
 455 
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DISCUSSION 456 
The continued interspecies transmission of IAVs to humans and other mammals is a 457 
constant threat (44-46, 4). As dogs are popular companion animals and can support the 458 
replication of multiple IAV subtypes such as H3N8, H3N1, H3N2, H5N1, H5N2 and 459 
H1N1 (47, 48, 10, 49-52, 11, 53-58), they could act as intermediate hosts for IAV 460 
reassortment or human exposure (7). Various human IAVs such as PR8, 461 
A/Udorn/307/72 H3N2 and pH1N1 replicate in the respiratory tract of the dog and viable 462 
reassortant viruses between H3N8 CIV and pH1N1 IAV have been reported (59). In 463 
addition, it has been shown that dogs can be co-infected by pH1N1 and H3N2 CIV, 464 
leading to the generation of viable reassortants (60, 53). This highlights the need for 465 
monitoring the evolution of CIVs and studying the mechanism of IAV adaptation to new 466 
hosts.  467 
IAVs possess mechanisms to antagonize host IFN and IFN-induced responses (61, 468 
62). IAV NS1 is a multifunctional viral protein and the main factor to counteract host 469 
innate immune responses, allowing the virus to efficiently replicate during infection (63, 470 
18). One mechanism of inhibition of innate immune responses is mediated through the 471 
binding of IAV NS1 to CPSF30, which blocks the processing of pre-mRNAs in the 472 
nucleus and suppresses the expression of host genes, including IFN and ISGs (26, 29, 473 
30, 25, 28, 31-34). However, CPSF30-binding is not essential for successful IAV 474 
infection since some NS1 proteins do not bind CPSF30 (26, 29, 30, 25, 28, 31-34). The 475 
reasons for such variation are not well understood. However, it could be possible that in 476 
mammals, the lack of inhibition of important host genes (e.g. cytokines) prevents 477 
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infection by other pathogens that could interfere and/or compete with viral replication 478 
and dissemination. 479 
Our results show that H3N8 CIV NS1 protein inhibits the induction of IFN and ISGs 480 
(Fig. 5), but does not bind CPSF30 (Fig. 4) and therefore is unable to block host gene 481 
expression in either canine or human cells (Fig. 1). NS1 residue 186 proved to be a 482 
main determinant in blocking general gene expression (Fig. 2), and the K186E 483 
substitution introduced both the NS1-CPSF30 interaction (Fig. 4) and gene expression 484 
inhibition (Fig. 2). This inhibition of host gene expression was dose dependent and 485 
specific for polymerase II nuclear expressed transcripts (Fig. 3).  486 
Our results are consistent with previous work using A/Udorn/72 H3N2 NS1 protein, 487 
where residues around position 186 (amino acids 184 to 188; GLEWN) are important for 488 
binding to CPSF30 and inhibiting host gene expression (32), and were important for 489 
efficient viral replication (32). Interestingly, we found that CIV NY09 K186E replicated 490 
better than the WT virus in two canine cell lines, but only at high MOI (Fig. 6). 491 
Moreover, while both viruses were able to inhibit induction of IFN to a similar extend, 492 
CIV NY09 mutant K186E inhibited the expression of ISG more efficiently than WT virus 493 
(Fig. 7). However, the different abilities of CIV NY09 NS1 WT and K186E proteins to 494 
block host gene expression could have a more significant role in the natural host, the 495 
dog. 496 
Our study also confirms that NS1 binding to CPSF30 and the resulting block in 497 
general gene expression does not impair the ability of this NS1 to counteract IFN 498 
induction (Fig. 5). As indicated for other IAVs (27, 30, 18, 25, 33, 34) our results clearly 499 
show that the NS1 proteins of different IAV strains that infect the same host can differ in 500 
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their strategy to overcome the innate immune response. We showed that the avian-501 
origin H3N2 CIV NS1 protein -which contains E186- inhibits host gene expression (Fig. 502 
10) and that the same is observed with A/equine/Miami/63, an early EIV (the ancestor of 503 
H3N8 CIV) that possess E186 (Fig. 8). As both EIV H3N8 and H3N2 CIV are avian-504 
origin viruses, E186 might be important during the initial stages of IAV adaptation in 505 
mammals (Chauche, Nogales et al., submitted) and that K186 provides increased 506 
fitness at later evolutionary stages. Notably, since introduced in EIV in the early 70s, 507 
amino acid substitution E186K has remained stable in both EIV and CIV strains (Fig. 9). 508 
It has been recently reported that the PA-X protein from both H3N8 EIVs and CIVs 509 
are able to suppress host gene expression (64). It is possible that EIV and CIV H3N8 510 
NS1 proteins lost the ability to inhibit gene expression because of the ability of the viral 511 
PA-X to suppress host protein expression (64). In fact, we have recently described that 512 
inhibition of host protein expression by influenza virus is subject to a strict balance, 513 
which can determine the successful progression of viral infection (65). Thus, it is 514 
possible that H3N8 EIV and CIV NS1 proteins lost the ability to interact and inhibit 515 
CPSF30 to improve viral fitness since this function is carried out by the viral PA-X 516 
protein (64) and viruses encoding PA-X and NS1 proteins able to inhibit host gene 517 
expression would not be as fitted as viruses where only one of the viral proteins is able 518 
to inhibit host gene expression (65). It remains to be determined whether or not CIV 519 
H3N2 PA-X does inhibit host gene expression to the same extend than H3N8 EIV 520 
and/or CIV PA-X proteins.  521 
In sum, our study provides insights into the mechanisms employed by IAVs to 522 
counteract the innate immune response in different hosts and also how those can vary 523 
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depending on the virus origin and the strain involved. Future in vivo studies using these 524 
viruses will shed light on the role of NS1 protein in pathogenicity, transmission efficiency 525 
and mammalian adaptation in natural hosts. 526 
 527 
 528 
 529 
 530 
 531 
 532 
 533 
 534 
 535 
 536 
 537 
 538 
 539 
 540 
 541 
 542 
 543 
 544 
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FIGURES 567 
Figure 1. H3N8 CIV NS1 protein does not inhibit general gene expression in 568 
human HEK293T or canine MDCK cells. HEK293T (A-C) and MDCK (D-F) cells (12-569 
well plate format, 3x105 cells/well, triplicates) were transiently co-transfected with 50 ng 570 
of pCAGGS expression plasmids encoding GFP and Gluc together with 2 µg of 571 
pCAGGS plasmids encoding the indicated NS1 proteins fused to an HA-tag, or empty 572 
(E) plasmid as control. At 24 hpt, cells were analyzed for GFP expression using a 573 
fluorescent microscope (A and D) and Gluc activity from TCS (B and E). NS1 protein 574 
expression levels (C and F) from total cell lysates were determined by Western blot 575 
using an anti-HA polyclonal antibody (HA-NS1). Actin was included as a loading control. 576 
Representative images of three independent transfections are shown. Scale bar = 100 577 
μm. Results represent the means and standard deviation of triplicate values. *, p<0.005 578 
using Student’s t test. PR8: influenza A/Puerto Rico/8/34 H1N1; BM/18: A/Brevig 579 
Mission/01/1918 H1N1; CIV NY09: A/canine/NY/dog23/2009 H3N8.  580 
Figure 2. A single amino acid substitution (K186E) restores H3N8 CIV NS1’s 581 
ability to block host gene expression. A) Amino acid sequence alignment of IAV 582 
NS1 proteins: Residues 70 to 194 from NS1 proteins that do not inhibit (PR8 and 583 
pH1N1) or inhibit (BM/18 and TX/91) host gene expression were aligned to H3N8 CIV 584 
NY09 NS1 protein (bottom). Gray shadow highlights amino acid changes in the H3N8 585 
CIV NY09 NS1 effector domain, which could have a role in the lack of inhibition of host 586 
gene expression (P77, D96, T112, E139, F185, K186, K193 and I194). Abbreviations 587 
are as those described in Figure 1 legend. pH1H1: A/California/04/09 H1N1; TX/91: 588 
A/Texas/36/91 H1N1. B-D) Inhibition of host gene expression:  MDCK cells (12-well 589 
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plate format, 3x105 cells/well, triplicates) were transiently co-transfected with pCAGGS 590 
plasmids encoding GFP and Gluc (50 ng) together with plasmids encoding the indicated 591 
HA-tagged H3N8 CIV WT or single amino acid mutant (2 µg) NS1s, or empty (E) 592 
plasmid as control. At 24 hpt, cells were analyzed for GFP (B) and Gluc (C) expression. 593 
NS1 protein expression levels from total cell lysates were determined by Western blot 594 
using an anti-HA polyclonal antibody (HA-NS1) (D). Actin was included as a loading 595 
control. Representative images of three independent transfections are shown. Scale bar 596 
= 100 μm. Gluc expression levels in cells transfected with H3N8 CIV NS1 WT protein 597 
were considered 100% for comparison to expression levels from H3N8 CIV NS1 single 598 
amino acid individual mutant transfected cells. Results represent the means and 599 
standard deviation of triplicate values. *, p<0.05 using Student’s t test. 600 
Figure 3. Characterization of H3N8 CIV NS1 K186E mutation. A-B) Inhibition of 601 
host gene expression: MDCK cells (12-well plate format, 3x105 cells/well, triplicates) 602 
were transiently co-transfected as described in Figure 1, using different amounts of 603 
plasmids encoding N-terminal HA-tagged H3N8 CIV NS1 WT or K186E proteins. The 604 
total amount of transfected plasmid DNA was maintained constant with empty plasmid. 605 
At 24 hpt, cells were analyzed for Gluc activity from TCS (A). NS1 protein expression 606 
levels were determined by Western blot using an anti-HA polyclonal antibody (HA-NS1) 607 
and actin as a loading control (B). C-E) H3N8 CIV NS1 K186E does not inhibit T7-608 
driven RNA polymerase expression: Rodent BSRT7 cells (12-well plate format, 3x105 609 
cells/well, triplicates) constitutively expressing the T7 RNA polymerase were transiently 610 
co-transfected with the indicated NS1 expression plasmids or empty (E) plasmid as 611 
control (2 µg), together with GFP and FFluc T7-driven reporter pCITE-T7 plasmids (0.5 612 
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µg). At 24 hpt, GFP expression was evaluated under a fluorescent microscope (C) and 613 
Gluc activity was assessed from TCS (D). NS1 protein expression levels from total cell 614 
lysates were determined by Western blot using an anti-HA polyclonal antibody (HA-615 
NS1) (E). Actin was included as a loading control. Representative images of three 616 
independent transfections are shown. Scale bar = 100 μm. Results represent the means 617 
and standard deviation of triplicate values. *, p<0.05 using Student’s t test. 618 
Abbreviations are as those described in Figure 1 legend. 619 
Figure 4. K186E substitution in H3N8 CIV NS1 protein restores binding to 620 
CPSF30: A) Analysis of NS1-CPSF30 interaction by co-immunoprecipitation: A 621 
FLAG-tagged F2/F3 region of CPSF30 was expressed in HEK293T cells, mixed with in 622 
vitro synthesized PR8 or H3N8 CIV (WT or K186E) NS1 proteins and 623 
immunoprecipitated using an anti-FLAG resin. Following SDS-PAGE, input (top) and 624 
immunoprecipitated (IP, bottom) proteins were detected by Western blot using 625 
antibodies specific for the FLAG (region F2/F3 of CPSF30) or the HA (NS1s) tags. B) 626 
Tridimensional structure of NS1 effector domain in complex with the F2/F3 region 627 
of CPSF30: Influenza NS1 A/Udorn/72 H3N2 monomers conforming the dimer are 628 
shown in magenta or blue and the monomers of F2/F3 region of CPSF30 in green or 629 
brown. Amino acid residue K186 in influenza NS1 is indicated in yellow. The structure 630 
was generated with Cn3D and it is based on the NS1 of influenza A/Udorn/72 H3N2 631 
(PDB entry: 2RHK) (29). 632 
Figure 5. H3N8 CIV NS1 protein is an IFN antagonist: HEK293T cells (12-well plate 633 
format, 3x105 cells/well, triplicates) were transiently co-transfected, using CaPO4, with 634 
reporter plasmids encoding GFP and FFluc under the control of the IFN-β promoter 635 
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(pIFN-β-GFP/CAT and p IFN-β-FFluc, respectively) (0.5 µg) (A-C) or expressing RFP 636 
and FFluc under the control of an ISRE promoter (pISRE-RFP/CAT and pISRE-FFluc, 637 
respectively) (D-F), and the indicated N-terminal HA-tagged NS1 protein expressing 638 
plasmids, or empty (E) plasmid as control (1 µg). At 18 hpt, cells were infected (MOI 3) 639 
with SeV, Cantell strain, and 18 hpi, cells were analyzed for IFN-β (A-B) or ISRE (D-E) 640 
promoter activation by GFP (A) and RFP (D) expression under a fluorescent 641 
microscope, and FFluc activity (B and E). NS1 protein expression levels from total cell 642 
lysates were determined by Western blot using an anti-HA polyclonal antibody (HA-643 
NS1) (C and F). Actin was included as a loading control. Representative images of 644 
three independent transfections are shown. Scale bar = 100 μm. FFluc activity is 645 
represented as fold induction normalized to empty plasmid transfected, mock-infected 646 
cells. Results represent the means and standard deviation of triplicate values.  *, p<0.05 647 
using Student’s t test. Abbreviations are as those described in Figure 1 legend. 648 
Figure 6. Characterization of H3N8 NS1 WT and K186E CIVs. A) Phenotypic 649 
characterization: MDCK cells (6-well plate format, 1x106 cells/well) were infected (MOI 650 
of 3) with H3N8 NS1 WT and K186E CIVs. At 18 hpi RNA was collected and the NS 651 
viral segments were amplified by RT-PCR and undigested (-) or digested (+) with SwaI 652 
restriction endonuclease. DNA expected molecular sizes (nt) are indicated on the left. 653 
B) Plaque assay: Plaque sizes of H3N8 NS1 WT and K186E CIVs in MDCK cells (6-654 
well plate format, 1x106 cells/well) were evaluated at 3 days pi by immunostaining using 655 
an anti-NP monoclonal antibody (HB-65). C to F) Growth kinetics: MDCK  (C and D) 656 
or A72 (E and F) cells (12-well plate format, 5x105 cells/well, triplicates) were infected 657 
with low (C and E) or high (D and F) MOI (0.001 or 3, respectively) and TCS were 658 
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collected at the indicated hpi. Viral titers were determined by immunofocus assay 659 
(FFU/ml). Data represent the means of the results determined for triplicate wells. *, 660 
p<0.05 using Student’s t test.  661 
Figure 7. Induction of innate immune responses by H3N8 NS1 WT and K186E 662 
mutant CIVs: MDCK cells (12-well plate format, 5x105 cells/well, triplicates) were 663 
infected (MOI of 3) with H3N8 NS1 WT and mutant K186E CIVs. At 12 (A and C) or 24 664 
(B and D) hpi total RNA was collected and mRNA expression levels of the ISG IFIT2 (A 665 
and B) and IFNβ (C and D) were quantified by qRT-PCR analysis. Expression fold 666 
changes were calculated relative to mock-infected cells Data represent the average and 667 
standard deviation of triplicate values. *, p<0.05 using Student’s t test. 668 
Figure 8. The ability to block host gene expression was lost along the evolution of 669 
H3N8 EIV. A) Amino acid sequence alignment of H3N8 CIV and EIV NS1 proteins: 670 
Amino acid residues 161 to 230 from CIV NY09, A/canine/Florida/2004 (CIV FL04), 671 
A/equine/Pennsylvania/1/2007 (EIV Pen07) and A/equine/Miami/1963 (EIV Mi63) H3N8 672 
NS1 proteins are shown. Gray shadow highlights amino acid 186.  B-D) Amino acid 673 
186 is responsible for the lack of inhibition of host gene expression in H3N8 CIV 674 
and EIV NS1 proteins: MDCK cells (12-well plate format, 3x105 cells/well, triplicates) 675 
were transiently co-transfected with expression plasmids encoding GFP and Gluc (50 676 
ng), together with plasmids encoding the indicated H3N8 CIV or EIV WT and mutant 677 
NS1 proteins, or empty (E) plasmid as control (2 µg). At 24 hpt, cells were evaluated for 678 
GFP expression (B) or Gluc activity (C). NS1 protein expression levels from total cell 679 
lysates were determined by Western blot using an anti-HA polyclonal antibody (HA-680 
NS1) (D). Actin was included as a loading control. Scale bar = 100 μm. Results 681 
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represent the means and standard deviation of triplicate values. *, p<0.05 using 682 
Student’s t test. 683 
Figure 9. Frequency of identified NS1 186 mutation in H3N8 EIVs and CIVs 684 
isolates over time: Publicly available sequences in the Influenza Research database 685 
(www.fludb.org) were downloaded and the frequency of H3N8 EIV and CIV NS1 686 
sequences containing amino acids E186 or K186 are represented according to the 687 
years of virus isolation. 688 
Figure 10. The avian-origin H3N2 CIV NS1 protein is able to efficiently block host 689 
gene expression: MDCK cells (12-well plate format, 3x105 cells/well, triplicates) were 690 
transiently co-transfected with expression plasmids encoding GFP and Gluc (50 ng) 691 
together with plasmids encoding the indicated NH2 HA-tagged H3N8 or H3N2 CIV NS1 692 
proteins, or empty (E) plasmid as control (2 µg). At 24 hpt, cells were analyzed for GFP 693 
(A) and Gluc (B) expression. NS1 protein expression levels from total cell lysates were 694 
determined by Western blot using an anti-HA polyclonal antibody (HA-NS1) and actin 695 
was included as a loading control (C). Scale bar = 100 μm. Results represent the 696 
means and standard deviation of triplicate values. *, p<0.05 using Student’s t test. H3N8 697 
CIV: A/canine/NY/dog23/2009 H3N8; H3N2 CIV: A/canine/IL/41915/2015 H3N2. 698 
 699 
 700 
 701 
 702 
 703 
 704 
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